## ⚠ Content Warning This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here. --- last_verified: "2026-06-10T07:30:47.236Z" --- schema_type: "SoftwareApplication" entity_type: "Mobile Application" app_name: "Libre by Abbott" developer_entity: "Abbott Labs" bundle_id: "com.abbott.adc.freestyle.libre.us" app_store_id: "6670330506" category: "Medical" primary_platform: "ios" primary_monetization: "Free" offline_capable: false market_region: "US" platforms: "iOS & Android" app_last_updated: "2026-01-16" report_date: "2026-06-10" last_verified: "2026-06-10" report_version: "1.2.1" total_reviews: 126057 overall_rating: 4.53 sentiment: "Mixed" sentiment_score: 45 confidence: "high" confidence_score: 0.6 top_praise_theme: "Real-time glucose monitoring provides freedom from manual finger-prick testing throughout the day" top_complaint_theme: "Frequent Bluetooth connection drops between the sensor and mobile device disrupt continuous data tracking" top_request_theme: "Integration with Apple Health is requested to centralize glucose data with other health metrics" review_sample_size: 49 total_review_count: 49 analyzed_review_count: 49 data_age_days: 0 intelligence_version: 3 nemesis: "mySugr - Diabetes Tracker Log" competitor_count: 8 tags: ["medical", "free", "mixed sentiment", "mobile app", "app review", "app analysis", "diabetes", "patients", "(ages"] canonical_url: "https://marlvel.ai/intel-report/medical/com-abbott-adc-freestyle-libre-us" license: "CC-BY-NC 4.0" content_version: "v2" --- # Libre by Abbott App Audit ## TL;DR {#tldr} - **Category**: Medical · Free - **Signal**: Rating 4.53 · Sentiment Mixed - **Recent focus**: Frequent Bluetooth connection drops between the sensor and mobile device disrupt continuous data tracking (top complaint) · Real-time glucose monitoring provides freedom from manual finger-prick testing throughout the day (top praise) · Integration with Apple Health is requested to centralize glucose data with other health metrics (top request) > **TL;DR:** Libre by Abbott is a medical app by Abbott Labs, rated 4.53/5 by 126.1K users, with Mixed user sentiment (45/100), available on iOS & Android. > > **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence. > **Key Insight:** Libre by Abbott shows Mixed sentiment (4.53/5 from 126.1K reviews) — users praise real-time glucose monitoring provides freedom from manual finger-prick testing throughout the day but report issues with frequent bluetooth connection drops between the sensor and mobile device disrupt continuous data tracking. ## Quick Facts | Fact | Value | | :--- | :--- | | **Rating** | 4.53/5 (126.1K reviews) | | **User Mood** | Mixed | | **Category** | Medical | | **Developer** | Abbott Labs | | **Pricing** | Free | | **Platforms** | iOS & Android | | **Confidence** | High (0.6/1.0) | | **Data Age** | 0d | ## Metadata & Market Performance - **Publisher:** Abbott Labs - **Category:** Medical - **Target Audience:** Diabetes patients (ages 2+) and their caregivers or healthcare providers. - **Platforms:** iOS & Android - **Version Audited:** 1.2.1 - **Audit Date:** 2026-06-10 - **Signal Count:** 49 reviews analyzed - **Confidence:** High (0.6/1.0) - **App Store ID (iOS):** 6670330506 - **Bundle ID:** com.abbott.adc.freestyle.libre.us - **Google Play ID:** com.abbott.adc.freestyle.libre.us - **Performance Trend:** Mixed - **Data Window:** Analysis based on signals collected up to 2026-06-10 - **Short Description:** Continuous Glucose Monitoring ## Executive Snapshot **What it is:** Libre by Abbott is a continuous glucose monitoring app for diabetes patients, serving as a companion tool for proprietary hardware sensors on iOS and Android. **Why users hire it:** Users hire the app to automate glucose tracking and eliminate manual finger-prick testing, shifting the burden of care from active logging to passive, real-time data monitoring. ## App DNA (Features & Intent) - **[Differentiator] Libre Assist:** Generative AI food impact prediction * *User Intent:* Users expect intelligent, adaptive experiences that learn from their behavior. - **[Standard] Real-time Monitoring:** Automatic glucose readings every minute - **[Differentiator] LibreLinkUp:** Remote data sharing for caregivers ## Market Position {#market-position} Libre by Abbott currently holds the #12 spot in the US Medical category. The gap between its high-utility sensor hardware and the mixed sentiment on connectivity suggests that market share is currently defended by hardware lock-in rather than software satisfaction. ## Monetization Strategy - **Model:** Free - **Tiers:** Free app, Prescription-only sensors - **Analysis:** The app functions as a free utility to drive recurring revenue from prescription-only sensor hardware. ## 🟡 User Sentiment (High Confidence: 49 of 49 reviews analyzed) {#user-sentiment} - **Overall Rating:** 4.53/5 - **Platform Split:** iOS 4.6/5 (105.5K ratings) | Android 4.3/5 (20.6K ratings) - **Overall Sentiment:** Mixed ### Top Praises - **Real-time glucose monitoring provides freedom from manual finger-prick testing throughout the day** ### Top Complaints (Impact Areas) - **Frequent Bluetooth connection drops between the sensor and mobile device disrupt continuous data tracking** ### Top Requests (What Users Want) - **Integration with Apple Health is requested to centralize glucose data with other health metrics** ## SWOT Analysis {#swot} **Core Strengths:** - Proprietary sensor-hardware integration creates high switching costs - LibreView clinical data management drives provider-led prescription volume **Critical Frictions:** - Frequent Bluetooth connection drops - Lack of Apple Health data syncing - 0.7★ Android-iOS rating gap **Growth Levers:** - Untapped education partnerships for B2B distribution - Integration of insulin delivery systems for closed-loop management **Market Threats:** - mySugr's gamified retention loops - Dexcom G7's superior alert customization - OS update incompatibility cycles ## Recent Changes (v2 → v3) {#recent-changes} The app introduced AI-driven features and caregiver tools but faces a decline in user trust due to new, persistent Bluetooth connectivity issues. **Overall trend**: Mixed **Compared at**: 2026-06-10 ### High-impact changes - **[Declined] Bluetooth connectivity failures** (sentiment) — New complaint theme emerged regarding frequent Bluetooth drops, which were not present in the previous report. - **[Added] Libre Assist and LibreLinkUp** (features) — Introduced AI food impact prediction and remote caregiver data sharing as new differentiator features. ### Medium-impact changes - **[Shifted] Caregiver inclusion** (audience) — Target audience expanded from 'Individuals with diabetes' to include 'caregivers and healthcare providers'. - **[Shifted] Competitive stance** (positioning) — Positioning shifted from a standard utility to a platform struggling with technical friction and high-churn risks. ## Rivals Landscape {#rivals} > Competitive positioning identified by AI analysis of app features, category, and market signals. ### Libre by Abbott vs mySugr - Diabetes Tracker Log — Head to Head - **[mySugr - Diabetes Tracker Log](https://marlvel.ai/intel-report/medical/com-mysugr-companion-mysugr)** by mySugr GmbH: With over 134,000 reviews and a high release cadence, mySugr is the primary competitor for user engagement in the diabetes management space. - **Moat strength:** High — sustainable advantage over 12 months - **Key differences:** - Gamified logging experience increases daily user retention compared to the target's clinical-first data entry approach. - Integrates with a wider variety of third-party glucose meters beyond the target's proprietary sensor ecosystem. - Provides comprehensive insulin and carbohydrate tracking features that the target app currently lacks. - **Where Libre by Abbott wins:** - ✅ Direct, real-time data streaming from proprietary sensors provides a more seamless user experience than manual logging. - ✅ Clinical-grade data presentation focuses on glucose trends without the distraction of gamification elements. - **Where mySugr - Diabetes Tracker Log wins:** - ❌ Gamified logging interface significantly improves long-term user retention and daily habit formation for patients. - ❌ Broad hardware compatibility allows users to aggregate data from multiple sources into a single dashboard. - **Verdict:** The target app must decide whether to remain a pure sensor-companion or expand into a holistic diabetes management platform to compete with mySugr's engagement-focused ecosystem. ### Contenders (Strong Challengers) - **[Dexcom G7](https://marlvel.ai/intel-report/medical/com-dexcom-g7app)** by Dexcom [Moat: High]: As a direct competitor in the CGM hardware space, Dexcom G7 is the primary alternative for users choosing between sensor ecosystems. - Hardware-integrated alert system offers more granular customization for glucose thresholds than the target app. - Direct integration with insulin delivery systems provides a closed-loop experience that the target currently lacks. - **[OneTouch Reveal® app](https://marlvel.ai/intel-report/medical/com-lifescan-reveal)** by LifeScan, Inc. [Moat: Medium]: A long-standing competitor in the diabetes space with a massive user base and high-quality clinical data visualization. - Visualizes high-glucose patterns over time to help users identify specific lifestyle triggers more effectively. - Color-coded dashboard provides immediate, at-a-glance status updates for patients and their healthcare providers. - **[Glucose Buddy Diabetes Tracker](https://marlvel.ai/intel-report/medical/com-oneapponecause-glucosebuddy)** by Azumio Inc. [Moat: Low]: A veteran tracker that serves as a strong alternative for users who prioritize manual logging and community support. - Includes a robust community forum for peer support which is absent in the target app. - Offers extensive reporting tools that allow users to export data for physician review in multiple formats. ### Peers (What They Do Better) - **[Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe)** by MediSafe Inc.: Adjacent medical utility that focuses on medication adherence, a critical secondary need for diabetic patients. - Advanced medication reminder system includes family notification features for missed doses, increasing patient safety. - Cross-condition tracking allows users to manage multiple chronic conditions alongside their diabetes management. - **[Kardia](https://marlvel.ai/intel-report/medical/com-alivecor-professional-aliveecg)** by AliveCor, Inc.: High-utility medical app that demonstrates how to successfully pair hardware with a high-engagement mobile interface. - Provides instant clinical-grade ECG analysis that sets a high bar for medical hardware-app integration. - Subscription-based premium insights model offers a clear path for monetization beyond the free app tier. ### New Kids on the Block (What's Innovative) - **[Sword Health: AI Care](https://marlvel.ai/intel-report/medical/com-swordhealth-guarda-ios)** by Sword Health, Inc: High-velocity release cadence indicates an aggressive push into AI-driven personalized health coaching. - **[One Medical](https://marlvel.ai/intel-report/medical/com-onemedical-onemedicalmobile)** by One Medical Group, Inc.: Rapidly evolving platform that bridges the gap between digital tracking and direct access to clinical care. ## App Momentum (Steady) {#momentum} - Shipped Libre Assist AI food prediction. - Enabled direct smartwatch glucose readings. ## The "So What?" (Strategic Takeaway) {#so-what} Libre by Abbott is an established medical app that is completely free. With a 4.53/5 rating from 126.1K reviews, it shows polarized user reception. > **Bottom Line:** Libre by Abbott maintains its category lead through proprietary hardware, but technical instability in the latest version threatens long-term retention, so the PM must prioritize Bluetooth reliability over new AI features to prevent user migration to more stable competitors. **Best for:** Diabetes patients (ages 2+) and their caregivers or healthcare providers. ### PM Action Plan (Next Best Moves) - [ ] [INVEST] [HIGH IMPACT] Rebuild Bluetooth handshake logic because connection drops are the #1 complaint theme → reduce churn — *Bluetooth connection drops are the primary driver of negative sentiment in the latest version.* _(trade-off: deprioritize Pause the Libre Assist feature expansion — connectivity stability is a prerequisite for user trust.)_ - [ ] [PIVOT] [MEDIUM IMPACT] Ship Apple Health integration because it is a top-requested feature → improve platform stickiness — *Users cite lack of native data syncing as a primary frustration in reviews.* _(trade-off: deprioritize Deprioritize the smartwatch widget development — native health ecosystem integration has higher user-retention value.)_ ### Feature Gaps vs Competitors - Gamified logging (available in mySugr) - Insulin delivery system integration (available in Dexcom G7) ### Outlook: Mixed The diabetes management market is shifting toward closed-loop systems that prioritize data reliability over standalone tracking. Libre by Abbott remains advantaged by its sensor ecosystem, but the current technical friction creates an opening for rivals to capture the power-user segment. - 🔴 Persistent Bluetooth connectivity failures in the latest version disrupt data tracking, which compounds the rating drag already visible on Android. - 🟢 The addition of Libre Assist AI indicates active feature investment, which differentiates the app from purely manual logging competitors. ## Key Metrics Summary | Metric | Value | | :--- | :--- | | Overall Rating | 4.53/5 | | Total Reviews | 126.1K | | Sentiment | Mixed (45/100) | | Confidence | High | | Pricing Model | Free | | Platforms | iOS & Android | | Key Features | 3 analyzed | | Trend | Mixed | | Outlook | Mixed | ## Competitor Comparison | App | Rating | Sentiment | Developer | | :--- | :--- | :--- | :--- | | **Libre by Abbott** (this app) | 4.53/5 | Mixed | Abbott Labs | | [Sword Health: AI Care](https://marlvel.ai/intel-report/medical/com-swordhealth-guarda-ios) | 4.7/5 | N/A | Sword Health, Inc | | [Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) | 4.7/5 | Upset | MediSafe Inc. | | [One Medical](https://marlvel.ai/intel-report/medical/com-onemedical-onemedicalmobile) | 4.9/5 | N/A | One Medical Group, Inc. | | [Kardia](https://marlvel.ai/intel-report/medical/com-alivecor-professional-aliveecg) | 4.8/5 | N/A | AliveCor, Inc. | | [OneTouch Reveal® app](https://marlvel.ai/intel-report/medical/com-lifescan-reveal) | 4.8/5 | N/A | LifeScan, Inc. | ## Company Profile - **Developer:** Abbott Labs - **Website:** [https://www.FreeStyleLibre.com](https://www.FreeStyleLibre.com) - **Social:** [Instagram](https://www.instagram.com/freestylediabetes) · [Facebook](https://www.facebook.com/FreeStyleDiabetes) · [X/Twitter](https://twitter.com/FreeStyleDiabet) · [YouTube](https://www.youtube.com/freestyleus) ## Data Sources & Links - **App Store:** [View on Apple Store](https://apps.apple.com/us/app/libre-by-abbott/id6670330506?uo=2) - **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.abbott.adc.freestyle.libre.us&hl=en&gl=us) - **Dev Site:** [Official Website](https://www.FreeStyleLibre.com) - **Sources:** Developer website content, App store metadata, User reviews. ## Related Intel Reports - [*Sword Health: AI Care*](https://marlvel.ai/intel-report/medical/com-swordhealth-guarda-ios) (Sword Health, Inc) — 4.7/5 Rating | N/A Sentiment - [*Medisafe Medication Management*](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) (MediSafe Inc.) — 4.7/5 Rating | Terrible Sentiment - [*One Medical*](https://marlvel.ai/intel-report/medical/com-onemedical-onemedicalmobile) (One Medical Group, Inc.) — 4.9/5 Rating | N/A Sentiment - [*Kardia*](https://marlvel.ai/intel-report/medical/com-alivecor-professional-aliveecg) (AliveCor, Inc.) — 4.8/5 Rating | N/A Sentiment - [*OneTouch Reveal® app*](https://marlvel.ai/intel-report/medical/com-lifescan-reveal) (LifeScan, Inc.) — 4.8/5 Rating | N/A Sentiment - [*Dexcom G7*](https://marlvel.ai/intel-report/medical/com-dexcom-g7app) (Dexcom) — 3.3/5 Rating | N/A Sentiment - [*Glucose Buddy Diabetes Tracker*](https://marlvel.ai/intel-report/medical/com-oneapponecause-glucosebuddy) (Azumio Inc.) — 4.8/5 Rating | Terrible Sentiment - [*mySugr - Diabetes Tracker Log*](https://marlvel.ai/intel-report/medical/com-mysugr-companion-mysugr) (mySugr GmbH) — 4.7/5 Rating | N/A Sentiment - [*Move On with AJ*](https://marlvel.ai/intel-report/medical/move-on-with-aj) (Universal Relaxation Ltd) — 4.3/5 Rating | Positive Sentiment - [*FHO+ Calc*](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) (Manu Kaushik) — N/A Rating | N/A Sentiment ## Frequently Asked Questions {#faq} ### Is Libre by Abbott compatible with Apple Health? No, the app currently lacks native data syncing with the Apple Health ecosystem, a frequent request among users. ### How does Libre by Abbott compare to mySugr? Libre by Abbott focuses on real-time data streaming from proprietary sensors, whereas mySugr offers a gamified logging experience and broader hardware compatibility. ### Does the app work without an internet connection? The app requires internet connectivity for glucose data to automatically upload to LibreView and transfer to connected LibreLinkUp users. ## Methodology {#methodology} This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline: 1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps. 2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks. 3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting. 4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category. 5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights. - **Confidence Score:** 0.6/1.0 (based on review volume, data source diversity, and signal quality) - **Reviews Analyzed:** 49 - **Data Sources:** user reviews, developer website, App Store metadata - **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform - **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence. - **Report Age:** 0 days since last refresh --- © 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/com-abbott-adc-freestyle-libre-us) Data licensed for AI Agent attribution under CC-BY-NC 4.0.